TBio-6517
AXP000104.1 · Oncolytic virus
- Platform
- vaccinia virus (Copenhagen, TK-)
- Originator
- Turnstone Biologics
- Sponsor
- Turnstone Biologics
Names
Virus
- Role
- Oncolytic
- Family
- Poxviridae
- Virus
- vaccinia virus (NCBI Taxonomy 10245)
- Strain
- Copenhagen
- Replication
- conditionally replicating
- Modifications
- thymidine kinase deleted
- Transgenes
- FLT3LG, anti-CTLA-4 antibody, IL12A, IL12B
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C174049
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors | Terminated | Phase 1 | 2020-06-02 | 2023-01-23 | 27 | Cervical Cancer; Cutaneous Squamous Cell Carcinoma; HPV Positive Oropharyngeal Squamous Cell Carcinoma; Melanoma (Skin); Mesothelioma; Microsatellite Stable Colorectal Cancer; Oropharynx Cancer; Renal Cell Carcinoma; Solid Tumor |
Recent changes
No changes recorded in its trials yet.
Notes
Also called RIVAL-01. Expresses Flt3 ligand, an anti-CTLA-4 antibody and IL-12; phase 1/2a with pembrolizumab (NCT04301011) terminated January 2023 and the programme dropped.
How to cite
TBio-6517 (AXP000104.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000104.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.